Should I buy or sell Veracyte stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VCYT shares. View VCYT analyst ratings or view top-rated stocks .

What is Veracyte's stock price target for 2024?

5 brokerages have issued twelve-month target prices for Veracyte's shares. Their VCYT share price targets range from $21.00 to $34.00. On average, they predict the company's stock price to reach $29.00 in the next year. This suggests a possible upside of 49.1% from the stock's current price. View analysts price targets for VCYT or view top-rated stocks among Wall Street analysts .

How have VCYT shares performed in 2024?

Veracyte's stock was trading at $27.51 at the start of the year. Since then, VCYT shares have decreased by 29.3% and is now trading at $19.45. View the best growth stocks for 2024 here .

Are investors shorting Veracyte?

Veracyte saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,640,000 shares, an increase of 32.8% from the March 15th total of 2,740,000 shares. Based on an average daily trading volume, of 633,600 shares, the short-interest ratio is currently 5.7 days. View Veracyte's Short Interest .

When is Veracyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our VCYT earnings forecast .

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) posted its quarterly earnings data on Thursday, February, 22nd. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03. The biotechnology company had revenue of $98.20 million for the quarter, compared to the consensus estimate of $95.49 million. Veracyte had a negative trailing twelve-month return on equity of 2.02% and a negative net margin of 20.61%.

What ETFs hold Veracyte's stock?

ETFs with the largest weight of Veracyte (NASDAQ:VCYT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM) , Global X Telemedicine & Digital Health ETF (EDOC) , ARK Genomic Revolution ETF (ARKG) , Invesco Biotechnology & Genome ETF (PBE) , ROBO Global Healthcare Technology and Innovation ETF (HTEC) , ARK Innovation ETF (ARKK) , WisdomTree BioRevolution Fund (WDNA) and ARK Next Generation Internation ETF (ARKW) .

What guidance has Veracyte issued on next quarter's earnings?

Veracyte issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $394.0 million-$402.0 million, compared to the consensus revenue estimate of $393.3 million.

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN) , Invitae (NVTA) , AbbVie (ABBV) , Xtrackers California Municipal Bond ETF (CA) , CRISPR Therapeutics (CRSP) , Advanced Micro Devices (AMD) , Editas Medicine (EDIT) , NVIDIA (NVDA) , Exelixis (EXEL) and NeoGenomics (NEO) .

Who are Veracyte's major shareholders?

Veracyte's stock is owned by many different retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (4.46%), Diversified Trust Co (0.03%), Los Angeles Capital Management LLC (0.03%), Artemis Investment Management LLP (0.01%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Bonnie H Anderson , Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy , Jens Holstein , John L Bishop, Karin Eastham , Marc Stapley and Muna Bhanji. View institutional ownership trends .

How do I buy shares of Veracyte?

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Veracyte have any subsidiaries?

The following companies are subsidiares of Veracyte: Allegro Diagnostics, Decipher Biosciences Inc., Decipher Corp., Delight Merger Sub II LLC, HalioDx Inc., Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS. Read More

NASDAQ:VCYT

Veracyte (VCYT) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free VCYT Stock Alerts

$19.45

+0.25 (+1.30%)

(As of 04/19/2024 ET)

Compare

Today's Range: $19.02
▼
$19.54
50-Day Range: $18.86
▼
$26.52
52-Week Range: $18.61
▼
$30.52

Volume: 1.36 million shs
Average Volume: 639,015 shs
Market Capitalization: $1.46 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $29.00

Get Veracyte alerts:

Veracyte MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 49.1% Upside
$29.00 Price Target
Short Interest: Bearish
4.85% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.02
Upright™ Environmental Score
News Sentiment: 0.38
Based on 11 Articles This Week
Insider Trading: Selling Shares
$216,500 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.29) to $0.01 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.59 out of 5 stars

Medical Sector

249th out of 911 stocks

Medical Laboratories Industry

9th out of 20 stocks

3.3

Analyst's Opinion

Consensus Rating
Veracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Veracyte has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.85% of the outstanding shares of Veracyte have been sold short.
Short Interest Ratio / Days to Cover
Veracyte has a short interest ratio ("days to cover") of 5.7.
Change versus previous month
Short interest in Veracyte has recently increased by 32.85%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Veracyte does not currently pay a dividend.
Dividend Growth
Veracyte does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Veracyte has received a 67.11% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Diagnostic test kits", "Management consulting for the pharmaceutical industry", and "DNA sequencers" products. See details.
Environmental Sustainability
The Environmental Impact score for Veracyte is -1.02.

2.4

News and Social Media Coverage

News Sentiment
Veracyte has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Veracyte this week, compared to 3 articles on an average week.
Search Interest
1 people have searched for VCYT on MarketBeat in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $216,500.00 in company stock.
Percentage Held by Insiders
Only 2.60% of the stock of Veracyte is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Veracyte are expected to grow in the coming year, from ($0.29) to $0.01 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Veracyte is -18.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Veracyte is -18.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Veracyte has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Veracyte Stock (NASDAQ:VCYT)

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

VCYT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VCYT Stock News Headlines

April 3, 2024 | insidertrades.com

Veracyte, Inc. (NASDAQ:VCYT) Director Karin Eastham Sells 10,000 Shares

April 17, 2024 | finance.yahoo.com

Veracyte, Inc. (VCYT)

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

April 16, 2024 | businesswire.com

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

April 16, 2024 | americanbankingnews.com

Veracyte (NASDAQ:VCYT) Price Target Lowered to $28.00 at The Goldman Sachs Group

April 16, 2024 | americanbankingnews.com

Veracyte (NASDAQ:VCYT) Hits New 1-Year Low on Analyst Downgrade

April 15, 2024 | americanbankingnews.com

Veracyte, Inc. (NASDAQ:VCYT) Short Interest Up 32.8% in March

April 12, 2024 | americanbankingnews.com

Veracyte (NASDAQ:VCYT) Shares Gap Down to $21.43

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 2, 2024 | finance.yahoo.com

What Makes Veracyte (VCYT) a Lucrative Investment?

March 16, 2024 | finance.yahoo.com

VCYT Apr 2024 30.000 call

February 27, 2024 | businesswire.com

Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

February 26, 2024 | investorplace.com

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff

February 26, 2024 | markets.businessinsider.com

Veracyte’s Strategic Growth and Market Positioning Inspire Positive Analyst Outlook

February 24, 2024 | finance.yahoo.com

Veracyte Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

February 23, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Veracyte (VCYT), Irhythm Technologies (IRTC)

February 23, 2024 | finance.yahoo.com

Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Call Transcript

February 22, 2024 | benzinga.com

Recap: Veracyte Q4 Earnings

February 22, 2024 | finance.yahoo.com

Veracyte Inc (VCYT) Reports 22% Revenue Growth in 2023, Maintains Positive Cash Flow Outlook

February 22, 2024 | seekingalpha.com

Veracyte, Inc. 2023 Q4 - Results - Earnings Call Presentation

February 22, 2024 | businesswire.com

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

February 21, 2024 | finance.yahoo.com

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference

February 21, 2024 | businesswire.com

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference

February 19, 2024 | finance.yahoo.com

VCYT Mar 2024 35.000 put

February 17, 2024 | finance.yahoo.com

VCYT Mar 2024 20.000 put

February 8, 2024 | finance.yahoo.com

Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

February 7, 2024 | msn.com

Veracyte Finalizes C2i Genomics Acquisition Deal

See More Headlines

Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medical laboratories
Sub-Industry: N/A
Current Symbol: NASDAQ:VCYT
CUSIP: N/A
CIK: 1384101
Web: www.veracyte.com
Phone: (650) 243-6300
Fax: 650-243-6301
Employees: 815
Year Founded: 2006

Price Target and Rating

Average Stock Price Target: $29.00
High Stock Price Target: $34.00
Low Stock Price Target: $21.00
Potential Upside/Downside: +50.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-74,400,000.00
Net Margins: -20.61%
Pretax Margin: -21.22%
Return on Equity: -2.02%
Return on Assets: -1.89%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.66
Quick Ratio: 4.40

Sales & Book Value

Annual Sales: $361.05 million
Price / Sales: 4.01
Cash Flow: $0.09 per share
Price / Cash Flow: 203.21
Book Value: $14.30 per share
Price / Book: 1.35

Miscellaneous

Outstanding Shares: 75,070,000
Free Float: 73,116,000
Market Cap: $1.45 billion
Optionable: Optionable
Beta: 1.62

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Marc A. Stapley (Age 54)
CEO & Director
Comp: $1.25M
Ms. Rebecca Chambers (Age 45)
Executive VP & CFO
Comp: $772.41k
Ms. Annie McGuire (Age 43)
Executive VP, General Counsel & Chief People Officer
Comp: $633.65k
Mr. Jonathan Wygant (Age 53)
VP & Chief Accounting Officer
Mr. Steven French
Senior VP & Chief Information Officer
Dr. Phillip G. Febbo M.D. (Age 58)
Chief Scientific & Medical Officer
Ms. Karen Possemato
Senior Vice President of Corporate Marketing, Communications & Commercial Operations
Mr. Robert Brainin (Age 53)
Executive VP & Chief Business Officer
Dr. John Leite Ph.D.
Chief Commercial Officer for CLIA Business
Ms. Corinne Danan
Senior Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VCYT Stock Analysis - Frequently Asked Questions

Should I buy or sell Veracyte stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VCYT shares.
View VCYT analyst ratings or view top-rated stocks.
What is Veracyte's stock price target for 2024?: 5 brokerages have issued twelve-month target prices for Veracyte's shares. Their VCYT share price targets range from $21.00 to $34.00. On average, they predict the company's stock price to reach $29.00 in the next year. This suggests a possible upside of 49.1% from the stock's current price.
View analysts price targets for VCYT or view top-rated stocks among Wall Street analysts.
How have VCYT shares performed in 2024?: Veracyte's stock was trading at $27.51 at the start of the year. Since then, VCYT shares have decreased by 29.3% and is now trading at $19.45.
View the best growth stocks for 2024 here.
Are investors shorting Veracyte?: Veracyte saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,640,000 shares, an increase of 32.8% from the March 15th total of 2,740,000 shares. Based on an average daily trading volume, of 633,600 shares, the short-interest ratio is currently 5.7 days.
View Veracyte's Short Interest.
When is Veracyte's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our VCYT earnings forecast.
How were Veracyte's earnings last quarter?: Veracyte, Inc. (NASDAQ:VCYT) posted its quarterly earnings data on Thursday, February, 22nd. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03. The biotechnology company had revenue of $98.20 million for the quarter, compared to the consensus estimate of $95.49 million. Veracyte had a negative trailing twelve-month return on equity of 2.02% and a negative net margin of 20.61%.

What ETFs hold Veracyte's stock?: ETFs with the largest weight of Veracyte (NASDAQ:VCYT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Global X Telemedicine & Digital Health ETF (EDOC), ARK Genomic Revolution ETF (ARKG), Invesco Biotechnology & Genome ETF (PBE), ROBO Global Healthcare Technology and Innovation ETF (HTEC), ARK Innovation ETF (ARKK), WisdomTree BioRevolution Fund (WDNA) and ARK Next Generation Internation ETF (ARKW).
What guidance has Veracyte issued on next quarter's earnings?: Veracyte issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $394.0 million-$402.0 million, compared to the consensus revenue estimate of $393.3 million.
What other stocks do shareholders of Veracyte own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).
Who are Veracyte's major shareholders?: Veracyte's stock is owned by many different retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (4.46%), Diversified Trust Co (0.03%), Los Angeles Capital Management LLC (0.03%), Artemis Investment Management LLP (0.01%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John L Bishop, Karin Eastham, Marc Stapley and Muna Bhanji.
View institutional ownership trends.
How do I buy shares of Veracyte?: Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Veracyte have any subsidiaries?: The following companies are subsidiares of Veracyte: Allegro Diagnostics, Decipher Biosciences Inc., Decipher Corp., Delight Merger Sub II LLC, HalioDx Inc., Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.
Read More

This page (NASDAQ:VCYT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial